14576-66-0

Upstream product

• 112-30-1 1-Decanol 
• 76964-69-7 decyl-phosphonic acid dimethyl ester 
• 79-37-8 oxalyl dichloride 
• 16165-49-4 P-decylphosphonic acid, ethyl ester 
• 6874-60-8 1-decylphosphonic acid 

Downstream Products

• 21612-77-1 Decylphosphonsaeure-bis-<4-nitro-phenylester> 
• 4762-28-1 diphenyldecylphosphine oxide 
• 21612-78-2 Decylphosphonsaeure-dicyclohexylester 
• 60147-47-9 2-Decyl-2-oxo-1,3-dioxa-6-(β-oxyethyl)aza-2-phosphacyclooctane 
• 620623-28-1 C₇₀H₈₆F₆N₅O₁₅P 
• 21612-75-9 Decylphosphonsaeure-diphenylester 
• 21612-76-0 Decylphosphonsaeure-bis-<2-nitro-phenylester> 

Relevant academic research and scientific papers

Inhibition of human gastric and pancreatic lipases by chiral alkylphosphonates. A kinetic study with 1,2-didecanoyl-sn-glycerol monolayer

Enantiomerically pure alkylphosphonate compounds RR'P(O)PNP (R=C(n)H(2n+1), R'=OY with Y=C(n')H(2n'+1) with n=n' or n≠n'; PNP=p-nitrophenoxy) noted (RY), mimicking the transition state occurring during the carboxyester hydrolysis were synthesized and investigated as potential inhibitors of human gastric lipase (HGL) and human pancreatic lipase (HPL). The inhibitory properties of each enantiomer have been tested with the monomolecular films technique in addition to an enyzme linked immunosorbent assay (ELISA) in order to estimate simultaneously the residual enzymatic activity as well as the interfacial lipase binding. With both lipases, no obvious correlation between the inhibitor molar fraction (α50) leading to half inhibition, and the chain length, R or Y was observed. (R11Y16)s were the best inhibitor of HPL and (R10Y11)s were the best inhibitors of HGL. We observed a highly enantioselective discrimination, both with the pure enantiomeric alkylphosphonate inhibitors as well as a scalemic mixture. We also showed, for the first time, that this enantioselective recognition can occur either during the catalytic step or during the initial interfacial adsorption step of the lipases. These experimental results were analyzed with two kinetic models of covalent as well as pseudo-competitive inhibition of lipolytic enzymes by two enantiomeric inhibitors. Copyright (C) 1999 Elsevier Science Ireland Ltd.

DISACCHARIDES FOR DRUG DISCOVERY

Methods are described for the preparation of combinatorial libraries of potentially biologically active disaccharide compounds. These compounds are variously functionalized, with a view to varying lipid solubility size, function and other properties, with the particular aim of discovering novel drug or drug-like compounds, or compounds with useful properties. The invention provides intermediates, processes and synthetic strategies for the solution or solid phase synthesis of disaccharides, variously functionalised about the sugar ring, including the addition of aromaticity and charge, and the placement of pharmaceutically useful groups and isosteres.

Phosphorus containing compounds as antihypercholesterolemic and antiatherosclerotic agents

Novel phosphorus containing compounds are described, as well as methods for the preparation and pharmaceutical composition of same, which are useful in preventing the intestinal absorption of cholesterol and thus are useful in the treatment of hypercholesterolemia and atherosclerosis.